Mike Doustdar

The success we have had with obesity has meant that a lot of companies, pretty much all pharma companies out there, has gotten excited about what we do.

So that is good from a patient's perspective.

More players will come in.

From a shareholder perspective.

But at the same time, we have to make sure we can outperform the competition from a shareholder perspective.

So my job is to really make sure that we are ready for the headwind that we clearly are seeing coming towards us.

When are you going to match Eli Lilly in terms of performance?

They had results a few days ago.

They were knockout.

When are you going to be able to match that kind of performance?

You talk about a kind of performance culture here.

Again, my job is to put the patient in the center of what I do and not necessarily just my competitor.

We watch them.

We take all of our competitors seriously.

But there are hundreds of millions of people out there.

that are suffering from diabetes and obesity that no one is right now addressing.

My job is to sustainably lead ourselves towards that aim.

How does Metzera help you do that?

Metzera has some of the best complementary assets to our own phenomenal pipeline.

So when the ambition is in billions and not millions, you need basically all the great assets to get.